Similar to TCGA, CDX2-suppressed and non-CDX2-suppressed colon cancers did not differ significantly in their mean age, percentage of patients above 65 years old, or prevalence of metastatic disease (Table 4). Here, CDX2 is linked to malignant colon neoplasm.